James W Smithy
Overview
Explore the profile of James W Smithy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
552
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Smithy J, Schoenfeld A, Betof Warner A
Transplant Cell Ther
. 2025 Mar;
31(3S):S626-S634.
PMID: 40089331
The recent approval of lifileucel by the US Food and Drug Administration in February 2024 was the culmination of over 3 decades of research in adoptive cell therapy with tumor-infiltrating...
2.
Lochrin S, Kalvin H, Smithy J, Chen M, Momtaz P, Shoushtari A, et al.
JAMA Oncol
. 2025 Jan;
PMID: 39883427
No abstract available.
3.
Smithy J, Postow M
Cancer Cell
. 2024 Nov;
42(11):1813-1814.
PMID: 39486410
Combinatorial immunotherapy may improve the efficacy of neoadjuvant checkpoint inhibitors in locoregionally advanced melanoma. In this issue of Cancer Cell, Davar and colleagues report a promising phase 2 neoadjuvant trial...
4.
Peng X, Smithy J, Yosofvand M, Kostrzewa C, Bleile M, Ehrich F, et al.
bioRxiv
. 2024 Oct;
PMID: 39416145
Recent progress in multiplexed tissue imaging is advancing the study of tumor microenvironments to enhance our understanding of treatment response and disease progression. Cellular neighborhood analysis is a popular computational...
5.
Yosofvand M, Edmiston S, Smithy J, Peng X, Kostrzewa C, Lin B, et al.
bioRxiv
. 2024 Sep;
PMID: 39229153
The multiplexed immunofluorescence (mIF) platform enables biomarker discovery through the simultaneous detection of multiple markers on a single tissue slide, offering detailed insights into intratumor heterogeneity and the tumor-immune microenvironment...
6.
Smithy J, Kalvin H, Ehrich F, Shah R, Adamow M, Raber V, et al.
Clin Cancer Res
. 2024 May;
30(16):3407-3415.
PMID: 38767650
Purpose: The Adaptively Dosed ImmunoTherapy Trial (ADAPT-IT;NCT03122522) investigated adaptive ipilimumab discontinuation in melanoma based on early radiographic assessment. Initial findings indicated similar effectiveness compared with conventional nivolumab-ipilimumab (nivo-ipi). Exploratory biomarker...
7.
Smithy J, Chapman P
Cancer J
. 2024 Mar;
30(2):48-53.
PMID: 38527257
The widespread adoption of immune checkpoint inhibitors and small molecule inhibitors of the MAP kinase pathway has transformed the management of locally advanced and metastatic melanoma. Here, we provide a...
8.
Vanguri R, Smithy J, Li Y, Zhuang M, Maher C, Aleynick N, et al.
J Pathol
. 2023 Sep;
261(3):349-360.
PMID: 37667855
As predictive biomarkers of response to immune checkpoint inhibitors (ICIs) remain a major unmet clinical need in patients with urothelial carcinoma (UC), we sought to identify tissue-based immune biomarkers of...
9.
Smithy J, Luke J
Clin Cancer Res
. 2023 Apr;
29(13):2345-2347.
PMID: 37097465
In a retrospective analysis of patients with unresectable melanoma, higher pretreatment tissue densities of CD16+ macrophages were associated with clinical benefit from combined CTLA-4 and PD-1 blockade. With further validation,...
10.
Smithy J, Blouin A, Diamond L, Postow M
J Immunother Cancer
. 2022 Nov;
10(11).
PMID: 36442912
In January 2022, the US Food and Drug Administration granted regulatory approval to tebentafusp, a bispecific T cell receptor protein that targets melanoma antigen gp100 in the context of the...